{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:38:48Z","timestamp":1791052728113,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1017\/s1461145711001015","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T10:48:35Z","timestamp":1310035715000},"page":"543-549","source":"Crossref","is-referenced-by-count":54,"title":["D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease"],"prefix":"10.1093","volume":"15","author":[{"given":"Evgenia","family":"Gelfin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Korn-Lubetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uriel","family":"Heresco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5]]},"reference":[{"key":"key\n\t\t\t\t20170713084502_ref001","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated l-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"key\n\t\t\t\t20170713084502_ref002","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/PL00007758","article-title":"Pathoanatomy of Parkinson's disease","volume":"247","author":"Braak","year":"2000","journal-title":"Journal of Neurology"},{"key":"key\n\t\t\t\t20170713084502_ref003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01345244","article-title":"Direct and indirect presynaptic control of dopamine release by excitatory amino acids","volume":"14","author":"Ch\u00e9remy","year":"1998","journal-title":"Amino Acids"},{"key":"key\n\t\t\t\t20170713084502_ref004","volume-title":"Statistical Power Analysis for the Behavioural Science","author":"Cohen","year":"1998","edition":"2nd edn."},{"key":"key\n\t\t\t\t20170713084502_ref005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1471-4159.2003.01744.x","article-title":"Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum","volume":"85","author":"Dunah","year":"2003","journal-title":"Journal of Neurochemistry"},{"key":"key\n\t\t\t\t20170713084502_ref006","first-page":"153","article-title":"UPDRS development committee. The United Parkinson's disease rating scale","volume-title":"Recent Developments in Parkinson's Disease","author":"Fahn","year":"1987"},{"key":"key\n\t\t\t\t20170713084502_ref007","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"key\n\t\t\t\t20170713084502_ref008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA antagonists in Parkinson's disease","volume":"10","author":"Hallett","year":"2004","journal-title":"Pharmacological Therapeutics"},{"key":"key\n\t\t\t\t20170713084502_ref009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco-Levy","year":"2004","journal-title":"Biological Psychiatry"},{"key":"key\n\t\t\t\t20170713084502_ref010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biological Psychiatry"},{"key":"key\n\t\t\t\t20170713084502_ref011","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170713084502_ref012","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.10041","article-title":"Clinical neuropsychological, and morphometric correlates of apathy in Parkinson's disease","volume":"227","author":"Isella","year":"2002","journal-title":"Movement Disorders"},{"key":"key\n\t\t\t\t20170713084502_ref013","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson's disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"key\n\t\t\t\t20170713084502_ref014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","article-title":"High dose D-serine in the treatment of schizophrenia","volume":"121","author":"Kantrowitz","year":"2010","journal-title":"Schizophrenia Research"},{"key":"key\n\t\t\t\t20170713084502_ref015","volume-title":"Positive and Negative Syndrome Scale (PANSS) Rating Manual","author":"Kay","year":"1987"},{"key":"key\n\t\t\t\t20170713084502_ref016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1017\/S1740925X05000141","article-title":"D-serine as a putative glial neurotransmitter","volume":"3","author":"Mustafa","year":"2004","journal-title":"Neuron Glia Biology"},{"key":"key\n\t\t\t\t20170713084502_ref017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mds.10107","article-title":"Characterisation of striatal NMDARs involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat","volume":"17","author":"Nash","year":"2002","journal-title":"Movement Disorders"},{"key":"key\n\t\t\t\t20170713084502_ref018","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/1381612024607072","article-title":"NR2B selective NMDA receptor antagonists","volume":"8","author":"Nikam","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"key\n\t\t\t\t20170713084502_ref019","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.73.6.636","article-title":"Apathy in Parkinson's Disease","volume":"73","author":"Pluck","year":"2002","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"key\n\t\t\t\t20170713084502_ref020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0006-8993(00)02036-9","article-title":"Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys","volume":"31","author":"Schneider","year":"2000","journal-title":"Brain Research"},{"key":"key\n\t\t\t\t20170713084502_ref021","doi-asserted-by":"crossref","first-page":"9413","DOI":"10.1523\/JNEUROSCI.3190-05.2005","article-title":"D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices","volume":"25","author":"Shleper","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"key\n\t\t\t\t20170713084502_ref022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"key\n\t\t\t\t20170713084502_ref023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/syn.890190405","article-title":"Glutamate\/dopamine D1\/D2 balance in the basal ganglia and its relevance to Parkinson's disease","volume":"19","author":"Starr","year":"1995","journal-title":"Synapse"},{"key":"key\n\t\t\t\t20170713084502_ref024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01345240","article-title":"Antagonists of glutamate in the treatment of Parkinson's disease: from laboratory to the clinic","volume":"14","author":"Starr","year":"1998","journal-title":"Amino Acids"},{"key":"key\n\t\t\t\t20170713084502_ref025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02336139","article-title":"Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice","volume":"97","author":"Stauch Slusher","year":"1994","journal-title":"Journal of Neural Transmission \u2013 Genetics Section"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/15\/4\/543\/18561360\/15-4-543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:16:31Z","timestamp":1741306591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article-lookup\/doi\/10.1017\/S1461145711001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,5]]},"published-print":{"date-parts":[[2012,5]]}},"URL":"https:\/\/doi.org\/10.1017\/s1461145711001015","relation":{},"ISSN":["1469-5111","1461-1457"],"issn-type":[{"value":"1469-5111","type":"electronic"},{"value":"1461-1457","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}